生产企业：Cartherics
CTH-401 is an investigational allogeneic, off-the-shelf iPSC-derived CAR-NK cell therapy developed by Cartherics targeting the tumor antigen TAG-72. It is in preclinical development with an IND filing planned for late 2026 and first-in-human trials in ovarian cancer to follow. Endometriosis is also a target indication.
CTH-401 is an investigational allogeneic, off-the-shelf iPSC-derived CAR-NK cell therapy developed by Cartherics targeting the tumor antigen TAG-72. It is in preclinical development with an IND filing planned for late 2026 and first-in-human trials in ovarian cancer to follow. Endometriosis is also a target indication.
CTH-401 is being developed primarily for ovarian cancer as the lead indication. Cartherics also intends to evaluate CTH-401 in endometriosis. The company plans to file an Investigational New Drug (IND) application in late 2026, with first-in-human clinical trials in ovarian cancer to follow.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
